ICON (ICLR) Downgraded by BidaskClub

BidaskClub cut shares of ICON (NASDAQ:ICLR) from a buy rating to a hold rating in a report released on Friday morning.

A number of other research analysts have also recently commented on the company. Zacks Investment Research upgraded ICON from a hold rating to a buy rating and set a $132.00 price target on the stock in a research report on Tuesday, January 9th. Credit Suisse Group upgraded ICON to a buy rating and set a $131.00 price target on the stock in a research report on Friday, February 16th. ValuEngine upgraded ICON from a hold rating to a buy rating in a research report on Sunday, December 31st. Evercore ISI started coverage on ICON in a research report on Thursday, January 18th. They issued an outperform rating and a $126.00 price target on the stock. Finally, Mizuho set a $109.00 price target on ICON and gave the stock a hold rating in a research report on Wednesday, January 24th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average target price of $126.00.

How to Become a New Pot Stock Millionaire

ICLR stock opened at $111.38 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.29. The firm has a market cap of $6,023.54, a price-to-earnings ratio of 20.70, a PEG ratio of 1.75 and a beta of 0.42. ICON has a fifty-two week low of $76.46 and a fifty-two week high of $124.65.

ICON (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, February 15th. The medical research company reported $1.43 EPS for the quarter, topping the Zacks’ consensus estimate of $1.41 by $0.02. ICON had a return on equity of 27.55% and a net margin of 16.01%. The company had revenue of $455.10 million for the quarter, compared to analysts’ expectations of $455.66 million. During the same quarter last year, the business earned $1.33 earnings per share. ICON’s revenue was up 4.6% on a year-over-year basis. equities analysts expect that ICON will post 6.02 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. Aperio Group LLC boosted its stake in ICON by 4.6% in the fourth quarter. Aperio Group LLC now owns 15,640 shares of the medical research company’s stock valued at $1,754,000 after buying an additional 682 shares in the last quarter. GW&K Investment Management LLC boosted its stake in ICON by 6.5% in the fourth quarter. GW&K Investment Management LLC now owns 11,496 shares of the medical research company’s stock valued at $1,289,000 after buying an additional 700 shares in the last quarter. Stifel Financial Corp boosted its stake in ICON by 2.1% in the third quarter. Stifel Financial Corp now owns 36,545 shares of the medical research company’s stock valued at $4,160,000 after buying an additional 763 shares in the last quarter. Sentry Investment Management LLC boosted its stake in ICON by 2.1% in the fourth quarter. Sentry Investment Management LLC now owns 37,807 shares of the medical research company’s stock valued at $4,240,000 after buying an additional 763 shares in the last quarter. Finally, FineMark National Bank & Trust boosted its stake in ICON by 35.1% in the fourth quarter. FineMark National Bank & Trust now owns 3,855 shares of the medical research company’s stock valued at $432,000 after buying an additional 1,002 shares in the last quarter. 90.59% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “ICON (ICLR) Downgraded by BidaskClub” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3343004/icon-iclr-downgraded-by-bidaskclub.html.

ICON Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for ICON (NASDAQ:ICLR)

Receive News & Ratings for ICON Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

American Express  Receives Consensus Rating of “Hold” from Brokerages
American Express Receives Consensus Rating of “Hold” from Brokerages
IA Financial Group  Given Average Recommendation of “Hold” by Analysts
IA Financial Group Given Average Recommendation of “Hold” by Analysts
Head to Head Analysis: Caleres  vs. Rocky Brands
Head to Head Analysis: Caleres vs. Rocky Brands
SteadyMed  Given Daily News Sentiment Rating of 0.36
SteadyMed Given Daily News Sentiment Rating of 0.36
Jason Industries  Getting Somewhat Favorable Press Coverage, Study Shows
Jason Industries Getting Somewhat Favorable Press Coverage, Study Shows
Goodomy Reaches Market Capitalization of $3.10 Million
Goodomy Reaches Market Capitalization of $3.10 Million


Leave a Reply

© 2006-2018 Ticker Report. Google+.